Brii Biosciences Limited

SEHK:2137 Stock Report

Market Cap: HK$797.0m

Brii Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Zhi Hong

Chief executive officer

CN¥18.2m

Total compensation

CEO salary percentage40.8%
CEO tenure7yrs
CEO ownership4.6%
Management average tenure3.2yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19
Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26
Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12
Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24
We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

CEO Compensation Analysis

How has Zhi Hong's remuneration changed compared to Brii Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥265m

Mar 31 2024n/an/a

-CN¥220m

Dec 31 2023CN¥18mCN¥7m

-CN¥175m

Sep 30 2023n/an/a

-CN¥251m

Jun 30 2023n/an/a

-CN¥327m

Mar 31 2023n/an/a

-CN¥405m

Dec 31 2022CN¥14mCN¥7m

-CN¥484m

Sep 30 2022n/an/a

-CN¥1b

Jun 30 2022n/an/a

-CN¥2b

Mar 31 2022n/an/a

-CN¥3b

Dec 31 2021CN¥65mCN¥37m

-CN¥4b

Sep 30 2021n/an/a

-CN¥4b

Jun 30 2021n/an/a

-CN¥4b

Mar 31 2021n/an/a

-CN¥3b

Dec 31 2020CN¥22mCN¥5m

-CN¥1b

Dec 31 2019CN¥20mCN¥4m

-CN¥521m

Compensation vs Market: Zhi's total compensation ($USD2.48M) is above average for companies of similar size in the Hong Kong market ($USD229.92K).

Compensation vs Earnings: Zhi's compensation has increased whilst the company is unprofitable.

CEO

Zhi Hong (60 yo)

7yrs

Tenure

CN¥18,158,000

Compensation

Dr. Zhi Hong, PhD, co-founded Brii Biosciences Limited in 2018 and serves as its Executive Chairman of the Board, Chief Executive Officer & Executive Director since 2018. Prior to starting Brii Bio, Dr. Ho...

Leadership Team

NamePositionTenureCompensationOwnership
Zhi Hong
Co-founder7yrsCN¥18.16m4.58%
HK$ 36.5m
Ankang Li
Chief Financial & Strategy Officer3.8yrsCN¥12.48m0.20%
HK$ 1.6m
Eleanor de Groot
Chief Technology Officer2.4yrsno datano data
Brian Alvin Johns
Chief Scientific Officerless than a yearno datano data
Sarah Qiu
Associate Director of Investor Relationsno datano datano data
Karen Del Barrio Neuendorff
Chief People Officer & Head of Human Resources3yrsno datano data
Coy Stout
Head of Patient Advocacy3.3yrsno datano data
Lianhong Xu
Head of Discoveryno datano datano data
Qing Zhu
Head of China Research & Development4.5yrsno datano data
David Margolis
Chief Medical Officer4.3yrsno datano data
Susannah Cantrell
Chief Business Officer2.5yrsno datano data
Aleksandar Skuban
Head of Central Nervous System Diseases Therapy Area Head2.4yrsno datano data

3.2yrs

Average Tenure

55yo

Average Age

Experienced Management: 2137's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zhi Hong
Co-founder7yrsCN¥18.16m4.58%
HK$ 36.5m
Ankang Li
Chief Financial & Strategy Officer2.3yrsCN¥12.48m0.20%
HK$ 1.6m
Yiu Wa Tsui
Independent Non-executive Directorno dataCN¥620.00k0.012%
HK$ 94.8k
Gregg Alton
Independent Non-executive Directorno dataCN¥620.00k0.012%
HK$ 94.8k
Taiyin Yang
Independent Non-Executive Director2.3yrsCN¥832.00k0.030%
HK$ 237.6k
Martin J. Murphy
Independent Non-executive Directorno dataCN¥620.00k0.012%
HK$ 94.8k
Hui Tang
Independent Non-executive Directorno dataCN¥620.00k0.012%
HK$ 94.8k

2.3yrs

Average Tenure

64yo

Average Age

Experienced Board: 2137's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 11:33
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Brii Biosciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouChina International Capital Corporation Limited
Xiao Wei LinEverbright Securities Co. Ltd.
Geoffrey PorgesLeerink Partners LLC